Ausgabe 5/2006
Inhalt (12 Artikel)
Factors affecting the pharmacokinetic profile of MS-275, a novel histone deacetylase inhibitor, in patients with cancer
Milin R. Acharya, Judith E. Karp, Edward A. Sausville, Kyunghwa Hwang, Qin Ryan, Ivana Gojo, Jűrgen Venitz, William D. Figg, Alex Sparreboom
The effect of single agent oral fusaric acid (FA) on the growth of subcuta neously xenografted SCC-1 cells in a nude mouse model
James M. Ruda, Kirt S. Beus, Christopher S. Hollenbeak, Ronald P. Wilson, Brendan C. Stack Jr.
The selectivty and anti-metastatic activity of oral bioavailable butyric acid prodrugs
Ada Rephaeli, Michal Entin-Meer, Dikla Angel, Nataly Tarasenko, Tal Gruss-Fischer, Irena Bruachman, Don R. Phillips, Suzanne M. Cutts, Daphne Haas-Kogan, Abraham Nudelman
Disposition of 9-nitrocamptothecin and its 9-aminocamptothecin metabolite in relation to ABC transporter genotypes
William C. Zamboni, Ramesh K. Ramanathan, Howard L. McLeod, Sridhar Mani, Douglas M. Potter, Sandra Strychor, Lauren J. Maruca, Cristi R. King, Laura L. Jung, Robert A. Parise, Merrill J. Egorin, Todd A. Davis, Sharon Marsh
A phase I trial of the bombesin/gastrin-releasing peptide (BN/GRP) antagonist RC3095 in patients with advanced solid malignancies
G. Schwartsmann, L. P. DiLeone, M. Horowitz, D. Schunemann, A. Cancella, A. S. Pereira, M. Richter, F. Souza, A. Brondani da Rocha, F. H. Souza, P. Pohlmann, G. De Nucci
Phase I dose escalation study of pegylated liposomal doxorubicin (Caelyx®) in combination with topotecan in patients with advanced malignancies
Hervé Ghesquières, Sandrine Faivre, Latifa Djafari, Patricia Pautier, Catherine Lhommé, Stéphanie Lozahic, Kamel Djazouli, Jean-Pierre Armand, Eric Raymond
Phase 1 trial of Anvirzel™ in patients with refractory solid tumors
Tarek Mekhail, Hanspreet Kaur, Ram Ganapathi, G. Thomas Budd, Paul Elson, Ronald M. Bukowski
Phase II study of vinflunine in patients with metastatic renal cell carcinoma
D. Goldstein, S. P. Ackland, D. R. Bell, I. N. Olver, I. D. Davis, M. A. Rosenthal, G. C. Toner, M. C. Pinel, M. Byrne
A phase II study of perifosine (D-21226) in patients with previously untreated metastatic or locally advanced soft tissue sarcoma: A National Cancer Institute of Canada Clinical Trials Group trial
M. Knowling, M. Blackstein, R. Tozer, V. Bramwell, J. Dancey, N. Dore, S. Matthews, E. Eisenhauer
A multi-center phase II study of BMS-247550 (Ixabepilone) by two schedules in patients with metastatic gastric adenocarcinoma previously treated with a taxane
J. A. Ajani, H. Safran, C. Bokemeyer, M. A. Shah, H.-J. Lenz, E. Van Cutsem, H. A. Burris III, D. Lebwohl, B. Mullaney
Phase II study of mitomycin-C, adriamycin, cisplatin (MAP) and Bleomycin-CCNU in patients with advanced cancer of the anal canal: An eastern cooperative oncology group study E7282
Minaxi Jhawer, Sridhar Mani, Myrto Lefkopoulou, Richard G. Hahn, Jules Harris, Paul J. Catalano, Daniel Haller
Abraxane® induced life-threatening toxicities with metastatic breast cancer and hepatic insufficiency
J. Lee Villano, Divyesh Mehta, Latha Radhakrishnan